Skip to content
  • About
  • Shop
  • News
  • Contact Us
Search
Please note: NECA will be closed from Friday 22nd December, reopening on Monday 8th January
NECA Logo
  • NET Nurse
  • Donate
  • What are NETs?
  • Patients & Carers
  • Healthcare Professionals
  • Get Involved
  • What are Neuroendocrine Cancers?
  • What are Pheos & Paras?
  • NET Symptoms
  • Causes
  • Treatments
  • Grades
National Action Plan
  • Patient & Carer Support
  • Patient Resources
  • Optimal Care Pathway
  • NET Nurse
  • Patient Stories
  • Share your Story
  • Australian NET Specialists
  • Clinical Trials
  • Living with NETS
National Action Plan
  • Optimal Care Pathway
  • Professional Learning
  • Patient Referral
  • Clinical Trials
  • NET Symptoms
  • Australian NET Specialists
  • Request an In-Service
  • PLANET Registry
  • Order Booklets & Resources
National Action Plan
  • Advocate for Us
  • Share your Story
  • Donate
  • Fundraise
  • Events
  • In Memoriam
  • Corporate Partners
  • Gifts & Wills
  • Volunteer
National-Action-Plan-1.png
NET Nurse
Donate

Home » General » CDA Stakeholder Forum

CDA Stakeholder Forum

  • March 30, 2014
On March 26th and 27th the Unicorn Foundation joined together with 16 other cancer patient groups to lend our voice as consumers, to the Cancer Drugs Alliance Stakeholder Forum held in Canberra.

The groups represented at the Forum included Bowel Cancer Australia, Brain Tumour Alliance Australia, Breast Cancer Network Australia, CanSpeak, Melanoma Patients Australia, Cancer Voices, Leukaemia Foundation, Lung Foundation Australia, John Logan Cancer Treatment Foundation, Lymphoma Australia, Unicorn Foundation, Myeloma Foundation of Australia, Palliative Care Australia, GI Cancer Institute, Australian Thyroid Foundation and Rare Cancers Australia.

Some key points out of the Forum were:

  • This is the first time this breadth of stakeholders across our cancer community has come together.
    During the two days, we challenged ourselves to address the urgent issues preventing Australian patients gaining timely access to cancer medicines.
  • We heard from local and international thought leaders and connected across a range of organisations and interest groups.
  • The Forum reinforced to us the seriousness of the cancer challenge and the need for a more proactive collaborative approach moving forward.  There was clearly a real appetite for moving forward with this agenda.

The key issues we explored were:

  • How we ensure the consumer voice truly gets heard
  • How we help inform evidentiary requirements, and
  • How we shape a fit-for-purpose Australian system – one that is equitable, affordable and sustainable

From this, we uncovered real opportunities to start this effort, including:

  • Getting genuine consumer input and more clinical expertise in the PBS listing process
  • Increasing transparency from all stakeholders around decision making
  • Shaping innovative approaches to speeding up access and funding

The CDA has committed to undertaking these next steps as a result of the Forum: 

  1. Tap into the expertise and passion from all those who attended the Forum by asking people to commit to working groups that will move the agenda forward. 
  2. The CDA will support this collaboration by:
    • Sharing a high level summary of the Forum discussions and available presentations within the next two weeks.
    • Launching working groups to take the early opportunities to the next level. 
    • Clarifying up front on how we will drive progress and allow an opportunity for all to engage.
  3. It is anticipated that there will be four working groups around the following priorities:
    • Ensuring a meaningful and impactful public and consumer voice – this will look at such ideas as a community panel and cancer consumer representative on the Pharmaceutical Benefits Advisory Committee (PBAC).
    • System improvement – looking at things like improving managed entry, tiering in the submission process, greater oncology clinical expertise in the process and improved transparency.
    • Innovative access models – such ideas as adaptive licencing, provisional listing, flexible pricing and expedited approval.
    • Reducing red-tape – by reducing administrative burden on healthcare professionals, proper data-linkage and reducing the number of PBAC submissions where possible

About the Cancer Drugs Alliance

The Cancer Drugs Alliance is a not-for-profit multi-stakeholder organisation committed to achieving the best outcomes for Australian cancer patients. Membership comprises individuals and organisations, including practising oncologists, haematologists, cancer patient support groups and advocacy organisations, and pharmaceutical companies currently providing cancer treatments to the Australian community.

The Forum was hosted by the CDA and supported by a large number of organisations including Bowel Cancer Australia, Brain Tumour Alliance Australia, Breast Cancer Network Australia, CanSpeak, Cancer Council Australia, Leukaemia Foundation, Lung Foundation Australia, Medicines Australia, Rare Cancers Australia, Unicorn Foundation, Australian Private Hospitals Association and the GI Cancer Institute. 

It follows on from the release last year of the Deloitte Access Economics report, Access to cancer medicines in Australia, and the 27 subsequent submissions received in response to the report from stakeholders.

A copy of the report and submissions is available at http://medicinesaustralia.com.au/issues-information/oncology-industry-taskforce/

Share this post

Subscribe to our eNews

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Recent posts

Sisters Full Moon Dip Fundraiser

November 28, 2023

Watercolours in Balmain fundraiser

November 21, 2023

CommNETS Conference – New Zealand

November 21, 2023

AGITG Annual Scientific Meeting – New Zealand

November 21, 2023
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousPharmaceutical Benefits Advisory Committee to Consider Everolimus for Metastatic Pancreatic Neuroendocrine Cancer
NextUnicorn Foundation Meets With Private Healthcare AustraliaNext

Related Posts

INCA Annual Summit 2023

The International Neuroendocrine Cancer Alliance (INCA) Annual Summit was held in Bologna on the 11 & 12 September 2023. It was such a productive 2

CNSA Annual National Congress 2023

CNSA Annual National Congress 2023 The 25th Cancer Nurses Society of Australia’s (CNSA) Annual Congress was held at the Adelaide Convention Centre June 14th – 16th 2023. The

NECA Finalist as NGO of the Year in Prime Awards

We’re thrilled to be announced as one of the finalists in the NGO of The Year category in the 2022 PRIME Awards Australia. The Prime

COVID-19 Information and Resources

A note from our CEO on COVID-19: To our wonderful NET community we stand with you and alongside you as we get through this unprecedented

View All

Make a difference

How much do you wish to donate?
$50
$100
$250
$500
$1000
Other

Subscribe to Newsletter

NECA Logo
registered charity badge

What are NETs

  • What Are Neuroendocrine Cancers?​
  • What Are Pheos & Paras?
  • National Patient Awareness
  • What Are Neuroendocrine Cancers?​
  • What Are Pheos & Paras?
  • National Patient Awareness

Patients & Carers

  • Patient & Carer Support
  • Patient Resources
  • Optimal Care Pathway
  • NET Nurse
  • National Action Plan
  • Patient Stories
  • Share your story
  • Australian NET Specialists
  • Clinical Trials
  • Living with NETS
  • Patient & Carer Support
  • Patient Resources
  • Optimal Care Pathway
  • NET Nurse
  • National Action Plan
  • Patient Stories
  • Share your story
  • Australian NET Specialists
  • Clinical Trials
  • Living with NETS

Healthcare Professionals

  • Optimal Care Pathway
  • Professional Learning
  • Patient Referral
  • Clinical Trials
  • NET Symptoms
  • Australian NET Specialists
  • Request an In-Service
  • PLANET Registry
  • Order Booklets & Resources
  • Optimal Care Pathway
  • Professional Learning
  • Patient Referral
  • Clinical Trials
  • NET Symptoms
  • Australian NET Specialists
  • Request an In-Service
  • PLANET Registry
  • Order Booklets & Resources

Get Involved

  • Advocate for us
  • Share your story
  • Donate
  • Fundraise
  • Events
  • In Memoriam
  • Corporate Partners
  • Gifts & Wills
  • Volunteer
  • Advocate for us
  • Share your story
  • Donate
  • Fundraise
  • Events
  • In Memoriam
  • Corporate Partners
  • Gifts & Wills
  • Volunteer
All charity donations to NeuroEndocrine Cancer Australia may be tax-deductible in Australia.

Registered Charity CFN 202607
© 2023 NeuroEndocrine Cancer Australia
  • Website by Five Creative
Twitter Facebook Youtube Instagram Linkedin

What's on?

Healthcare Professional Learning Modules.

Over 3,355 Healthcare Professionals Australia-wide have now enrolled in the free online, RACGP-approved Education Modules. Ask your GP to enrol today.

Get Involved